The estimated Net Worth of Mark L Baum is at least $90 Milión dollars as of 22 March 2024. Mr. Baum owns over 9,000 units of Harrow Health stock worth over $88,429,409 and over the last 11 years he sold HROW stock worth over $219,135. In addition, he makes $1,377,010 as Chief Executive Officer a Director at Harrow Health.
Sign up
Mr. Baum HROW stock SEC Form 4 insiders trading
Mark has made over 16 trades of the Harrow Health stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of HROW stock worth $104,310 on 22 March 2024.
The largest trade he's ever made was exercising 850,000 units of Harrow Health stock on 25 April 2021 worth over $35,164,500. On average, Mark trades about 85,147 units every 95 days since 2013. As of 22 March 2024 he still owns at least 2,137,525 units of Harrow Health stock.
You can see the complete history of Mr. Baum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Baum biography
Mark L. Baum J.D. serves as Chief Executive Officer, Director of the Company. In 2011, Mr. Baum led the restructuring and reorganization of Harrow and since that time has directed the creation, development and growth of the Company’s unique business model. Mr. Baum was appointed as a director of the Company in December 2011, served as the Chairman of the Board of Directors from December 2011 to April 2012, and was appointed as Chief Executive Officer in April 2012. Prior to Mr. Baum’s involvement with the Company, from 2001 to 2011, he was the founder and managing director of TBLF, LLC, a consulting firm and fund manager, where he managed a series of three funds and acted as a principal investor in financing publicly traded companies or bridge-to-public equity transactions. Before his fund management experience, Mr. Baum founded and served as the president of YesRx, and practiced as a U.S. securities lawyer focused on public company reporting requirements and finance-related matters. Mr. Baum is also a founder and board member of Eton Pharmaceuticals, Inc., Surface Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and our subsidiaries Mayfield Pharmaceuticals, Inc., and Radley Pharmaceuticals, Inc. From November 2012 until December 2017, Mr. Baum served on the board of directors for Ideal Power, Inc., where he was also chair of its audit committee. Mr. Baum brings years of public company executive and board experience, including knowledge of securities laws, reporting requirements and public company finance-related issues. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a graduate of California Western School of Law.
What is the salary of Mark Baum?
As the Chief Executive Officer a Director of Harrow Health, the total compensation of Mark Baum at Harrow Health is $1,377,010. There are no executives at Harrow Health getting paid more.
How old is Mark Baum?
Mark Baum is 47, he's been the Chief Executive Officer a Director of Harrow Health since 2012. There are 9 older and 2 younger executives at Harrow Health. The oldest executive at Harrow Health, Inc. is Dr. Robert J. Kammer D.D.S., 72, who is the Special Advisor.
What's Mark Baum's mailing address?
Mark's mailing address filed with the SEC is C/O HARROW, INC., 102 WOODMONT BLVD, SUITE 610, NASHVILLE, TN, 37205.
Insiders trading at Harrow Health
Over the last 6 years, insiders at Harrow Health have traded over $1,363,111 worth of Harrow Health stock and bought 1,487,560 units worth $12,882,479 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum a Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of $3,323,914. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth $199,400.
What does Harrow Health do?
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
What does Harrow Health's logo look like?
Complete history of Mr. Baum stock trades at Ideal Power Inc, Harrow Health a Eton Pharmaceuticals
Harrow Health executives and stock owners
Harrow Health executives and other stock owners filed with the SEC include:
-
Mark Baum,
Chief Executive Officer, Director -
Andrew Boll,
Chief Financial Officer, Corporate Secretary -
John Saharek,
President of ImprimisRx -
Mark L. Baum J.D.,
CEO & Chairman -
Andrew R. Boll C.F.A., C.M.A., CFA, CMA,
CFO & Corp. Sec. -
John P. Saharek,
Pres of ImprimisRx -
Richard Lindstrom,
Director -
Robert Kammer,
Independent Chairman of the Board -
Dr. Robert J. Kammer D.D.S.,
Special Advisor -
R. Lawrence Van Horn,
Independent Director -
Teresa Sparks,
Independent Director -
Larry Dillaha,
Chief Medical Officer -
Kim Barratt,
Chief Talent Officer -
Dr. Larry M. Dillaha M.D.,
Chief Medical Officer -
David Moufarrège,
VP of Technology -
Jamie Webb,
Director of Communications & Investor Relations -
Andrew Livingston,
Chief Innovation Officer -
Dr. Dennis E Saadeh Pharm.D.,
Chief of Formulation Strategy -
David Moufarrège,
VP of Technology -
Lauren P Silvernail,
Director -
Stephen G Austin,
Director -
Anthony Principi,
Director -
Management Inc. Opaleye,
10% owner -
Perry J. Sternberg,
Director -
Martin A. Makary,
Director